Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting patient impact. At the 2026 ASCO GU meeting, experts gathered to share the ...
An innovative care delivery model at Mayo Clinic integrates virtual oversight, remote patient monitoring, mobile health ...
14h
Clinical trial at Cleveland hospital leads to practice-changing precision prostate cancer therapy
A groundbreaking randomized clinical trial led by Chair of Radiation Oncology Daniel Spratt at University Hospitals Seidman Cancer Center in Cleveland has identified the first validated predictive ...
By Tim BakerClose readers of this blog and, indeed, the PCFA website, may have picked up on the carefully guarded secret that I have written a book ...
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 ...
The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.
In early trade, the ASX 300 stock jumped as much as 17% to $4.26 before pulling back. At the time of writing, the ...
ORNL is a leader both in developing advanced radiotherapies and in providing the radioisotopes needed for those therapies.
Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...
Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, research has demonstrated that combining ADT with additional agents ...
Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results